Trial NCT04399980, NCT04463004, NCT04492514
Publication Cremer P, Lancet Rheumatol, 2021
Primary outcome on the report: Proportion of patients alive and off supplemental oxygen therapy at day 14 after infusion of mavrilimumab or placebo

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.